#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4688	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2349	586.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1871	1871	T	710	T,C	611,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4688	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2349	586.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1605	1605	C	691	C	579	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7170	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	532.4	0	.	n	.	0	A9G	SNP	9	9	A	564	564	G	719	G,A	591,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7170	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	532.4	0	.	n	.	0	T695C	SNP	695	695	T	1250	1250	C	486	C,A	407,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7170	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	532.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2526	2526	C	662	C,T	562,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7170	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	532.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3152	3152	T	604	T,G	509,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7170	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4039	532.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2600	2600	A	657	A	566	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	710	folP	855	855	99.77	folP.l6.c4.ctg.1	1950	109.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1185	1187	AGC	159;160;161	A,C;G;C	136,1;139;144	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1570	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3921	120.1	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1336	1338	ATA	112;111;110	A;T;A	100;98;96	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1570	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3921	120.1	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1357	1359	ATA	106;107;106	A,G,C;T;A	86,1,1;89;92	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1570	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3921	120.1	1	SNP	p	S91F	0	.	.	271	273	TCC	880	882	TCC	135;137;136	T;C,T;C	116;117,1;118	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1570	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3921	120.1	1	SNP	p	D95G	0	.	.	283	285	GAC	892	894	GAC	135;135;136	G;A,G;C	119;116,1;119	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1570	gyrA	2751	2751	99.78	gyrA.l6.c4.ctg.1	3921	120.1	1	SNP	p	D95N	0	.	.	283	285	GAC	892	894	GAC	135;135;136	G;A,G;C	119;116,1;119	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	688	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1790	115.2	0	.	p	.	0	P191fs	FSHIFT	571	571	C	1146	1146	C	194	C	165	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	688	mtrR	633	633	99.69	mtrR.l15.c4.ctg.1	1790	115.2	1	SNP	p	G45D	0	.	.	133	135	GGC	707	709	GGC	187;188;190	G;G;C	161;161;161	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	442	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1387	95.6	0	.	n	.	0	.206T	INS	206	206	T	812	812	T	181	T	161	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1920	1922	GCC	146;147;146	G;C;C,A	125;123;124,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1962	1964	GCA	145;145;145	G;C;A	127;126;121	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	1	SNP	p	D86N	0	.	.	256	258	GAC	915	917	GAC	154;154;153	G;A;C	130;126;130	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	1	SNP	p	S87R	0	.	.	259	261	AGT	918	920	AGT	155;156;156	A,C;G;T	118,2;132;127	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	1	SNP	p	S87I	0	.	.	259	261	AGT	918	920	AGT	155;156;156	A,C;G;T	118,2;132;127	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	1	SNP	p	S87W	0	.	.	259	261	AGT	918	920	AGT	155;156;156	A,C;G;T	118,2;132;127	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1364	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3784	107.8	1	SNP	p	S88P	0	.	.	262	264	TCC	921	923	TCC	158;158;157	T;C;C	129;130;128	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	1356	parE	1986	1986	99.95	parE.l6.c30.ctg.1	3235	124.4	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1976	1978	GGT	182;182;180	G;G,T;T	151;149,1;144	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1478	1480	GCA	194;195;194	G;C,T;A	159;165,1;163	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1481	1483	ATC	194;193;194	A;T;C,A,T	157;160;161,1,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1493	1495	GTG	190;190;192	G;T;G	154;152;157	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1493	1495	GTG	190;190;192	G;T;G	154;152;157	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1997	1999	ACC	161;161;161	A;C;C,A	136;143;141,1	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2051	2053	GCG	162;163;165	G;C;G,A	138;129;131,1	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2051	2053	GCG	162;163;165	G;C;G,A	138;129;131,1	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2174	2176	GGT	150;149;148	G;G;T,C,G	126;130;126,1,1	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2183	2185	GGC	150;150;149	G,C;G;C,A	125,1;131;129,1	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1296	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2889	134.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2201	2203	CCG	140;141;140	C;C;G,T	119;126;122,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1486	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3372	131.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1790	1792	CTG	125;126;125	C;T;G	95;95;95	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	846	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2274	111.7	0	.	p	.	0	S22G	NONSYN	64	66	AGC	587	589	GGC	124;124;125	G;G,A;C	106;106,1;106	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	846	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2274	111.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	769	769	C	101	C	86	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	T18M	NONSYN	52	54	ACG	605	607	ATG	196;196;194	A;T;G	156;156;156	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	695	697	GGA	194;194;193	G;G;A	161;155;160	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	V75I	NONSYN	223	225	GTT	776	778	ATT	192;192;191	A;T;T	165;162;162	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	818	820	AGC	186;185;185	A;G;C	159;157;158	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	V98I	NONSYN	292	294	GTC	845	847	ATC	183;184;188	A,C;T;C	147,1;152;161	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	910	911	CG	183;183	C;G	158;153	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	913	915	CAG	181;180;182	C;A;G,C	152;152;151,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	917	919	AAA	184;185;184	A;A;A	154;161;156	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	944	946	TAT	179;177;176	T;A;T,G	149;146;145,3	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	N134K	NONSYN	400	402	AAT	953	955	AAG	172;173;174	A,C;A,C;G	146,1;147,1;151	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	V135F	NONSYN	403	405	GTG	956	958	TTT	173;173;171	T;T,C;T	149;149,1;145	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	G140K	NONSYN	418	420	GGA	971	973	AAA	164;163;163	A,C;A;A,G	142,1;140;135,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	980	982	GAA	165;163;163	G;A;A	144;137;140	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1004	1006	GCA	177;177;176	G;C;A	150;145;149	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1190	1192	TCA	169;171;170	T,G;C;A	141,1;142;144	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1310	1312	CAA	170;172;171	C;A;A	151;153;156	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	.	INDELS	760	762	ACA	1314	1318	ATCAA	170;170;169;170;170	A;T;C;A,G;A	155;152;156;155,1;152	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	.	INDELS	763	764	TG	1321	1323	AGT	170;171;170	A;G;T,G	156;158;154,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1328	1330	GAT	171;169;169	G;A,C;T	156;154,1;153	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1364	1366	AGC	179;181;179	A;G,C;C	163;155,1;157	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1436	1438	AGT	181;180;181	A;G;T	153;151;153	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1442	1444	GAC	181;180;181	G;A;C	151;149;152	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1445	1447	TAC	181;182;182	T,C;A;C,T	150,1;152;146,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	1	SNP	p	G120K	1	.	.	358	360	AAG	910	912	CGG	183;183;182	C;G;G	158;153;154	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	1	SNP	p	A121D	1	.	.	361	363	GAC	913	916	CGC	181;182;183	C;G,C;C	152;151,1;155	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	900	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2040	131.3	1	SNP	p	D121N	0	.	.	361	363	GAC	913	916	CGC	181;182;183	C;G,C;C	152;151,1;155	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2990	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5210	171.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2236	2238	CAT	177;176;174	C;A;T	156;150;152	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	488	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1495	97.5	1	SNP	p	V57M	1	.	.	169	171	ATG	747	749	ATG	185;185;186	A;T;G,T	163;163;160,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
